The future of the global uveitis treatment market looks promising with opportunities in the hospital pharmacy, drug stores & retail pharmacy, and online pharmacy markets. The global uveitis treatment market is expected to reach an estimated $965.4 million by 2030 with a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are worldwide rise in the frequency of chronic eye diseases and optical infections, rising geriatric population, as well as, government's implementation of policies that are advantageous to public health and the infrastructure for providing healthcare.
Some of the Key Questions answered in this exclusive report are:
Q.1. What are some of the most promising, high-growth opportunities for the uveitis treatment market by drug class (anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others), disease type (anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis), distribution channel (hospital pharmacies, drug stores & retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Market Segmentation:
In this market, anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies are the major segments of uveitis treatment market by drug class. Lucintel forecasts that anti-inflammatory will remain the largest segment over the forecast period because of the rising use of anti-inflammatory drugs as the initial line of treatment for uveitis.
Within this market, hospital pharmacy will remain the largest segment because the hospital patients have access to a large range of alternatives for managing ocular inflammation, as well as, hospitals treat and care for a sizable patient population.
APAC is expected to witness highest growth over the forecast period due to infrastructure improvements in the healthcare sector, an increase in the target population, the growth of the R&D sector, an increase in healthcare reforms, and technical developments in the healthcare industry in the region.
Santen Pharmaceutical, Allergan, Amgen, Bausch Health, Mylan, Clearside Biomedical, Eyepoint Pharmaceuticals, Novartis, Abbvie, and Alimera Sciences are the major suppliers in the uveitis treatment market.